Related Experiment Video
Updated: Jun 22, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Outcome of symptomatic intracranial atherosclerotic disease
Edgar A Samaniego1, Scott Hetzel, Supriya Thirunarayanan
1Department of Neurology, University of Wisconsin-Madison, Madison, Wisc, USA. esamanie@stanford.edu
Insights
Medical therapy and percutaneous transluminal angioplasty and stenting (PTAS) showed similar outcomes for patients with symptomatic intracranial atherosclerotic disease. Both treatments resulted in comparable rates of stroke, transient ischemic attack, and vascular death.
Area of Science:
- Neurology
- Vascular Medicine
- Interventional Cardiology
Background:
- Intracranial atherosclerotic disease carries a significant annual stroke risk (3.6%-22%).
- Evaluating treatment efficacy for symptomatic intracranial atherosclerotic disease is crucial for patient prognosis.
Purpose of the Study:
- To compare the natural history and prognosis of symptomatic intracranial atherosclerotic disease treated with medical therapy versus percutaneous transluminal angioplasty and stenting (PTAS).
Main Methods:
- Retrospective chart review of patients with symptomatic intracranial atherosclerotic disease (July 2004-September 2007).
- Patients were categorized into 'best medical therapy' or PTAS plus antiplatelet agents groups.
- Favorable outcome defined by absence of stroke, TIA, vascular death, mRS ≤3, and no reintervention for in-stent restenosis.
Main Results:
- 111 patients were analyzed: 58 in Medical Therapy Group and 53 in PTAS Group.
- Favorable outcomes were observed in 65.5% of the Medical Therapy Group and 69.8% of the PTAS Group.
- Combined ischemic endpoints (TIA, stroke, vascular death) were similar: 24% in Medical Therapy vs. 28.3% in PTAS.
Conclusions:
- The combined ischemic endpoint was statistically similar between the medical therapy and PTAS groups.
- This suggests comparable efficacy for both treatment strategies in managing symptomatic intracranial atherosclerotic disease.
Background And Purpose:
Patients with intracranial atherosclerotic disease have a 3.6% to 22% annual risk of stroke. In this study, we sought to evaluate the natural history and prognosis of patients with symptomatic intracranial atherosclerotic disease who received medical therapy versus percutaneous transluminal angioplasty and stenting (PTAS) at our institution.
Methods:
Charts of all patients with symptomatic intracranial atherosclerotic disease from July 2004 to September 2007 were reviewed and assessed for history of transient ischemic attack or stroke. Patients were either treated with "best medical therapy" (Medical Therapy Group) or PTAS plus antiplatelet agents (PTAS Group) and followed prospectively. A favorable outcome was defined as the absence of transient ischemic attacks, strokes, or vascular death; modified Rankin Scale of < or =3; and no endovascular reintervention of symptomatic in-stent restenosis.
Results:
One hundred eleven patients fulfilled entry criteria, with 58 (52.3%) and 53 patients (47.7%) enrolled in the Medical Therapy and PTAS Groups, respectively. Thirty-eight patients of the Medical Therapy Group (65.5%) had a favorable outcome compared with 37 patients of the PTAS Group (69.8%). Combined ischemic end point data for the occurrence of transient ischemic attack, stroke, and vascular death was similar with 14 (24%) events in the Medical Therapy Group versus 15 (28.3%) events in the PTAS Group.
Conclusions:
Overall, the combined ischemic end point was the same in the Medical Therapy and PTAS Groups.
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Ischemic Stroke l: Introduction
Atherosclerosis IV: Nursing Management
Aneurysm III: Interprofessional Care
